EGFR-TK-IN-1

• UNSPSC Description:

  EGFR-TK-IN-1 (compound 7o) is a potent mutant EGFR inhibitor with IC50 of 8.5 nM an 9.3 nM against EGFRL858R/T790M and EGFRDel19.EGFR-TK-IN-1 showes strong antiproliferative effects against EGFR mutant-driven non-small cell lung cancer (NSCLC) cells and induces cell apoptosis[1].

• Target Antigen:

  Apoptosis; EGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/egfr-tk-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=CC(NC1=CC=CC(N2C(COC3=CC=CC(OC)=C3)=CC4=CN=C(NC5=CC=C(N6CCC(N(C)C)CC6)C=C5)N=C42)=C1)=O

• Molecular Weight:

  617.74

• References & Citations:

  [1]Wang C, et al. Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment. Bioorg Chem. 2023 Dec 6;143:107004.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported